Chugai Pharma USA (CPUSA), a wholly-owned subsidiary of Japan’s Chugai Pharmaceutical, has announced the appointment of Athos Gianella-Borradori as Chief Medical Officer.
Dr Gianella-Borradori is an experienced pediatric hematologist-oncologist and executive with more than 20 years of international drug research and development experience, focusing on translational research and clinical development of novel therapeutic agents.
He has held senior positions in research and development at Novartis, Crucell, Bavarian Nordic, Cyclacel, Merck Serono and Clavis Pharma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze